1
Kristi A Leonard, Kent Barbay, James P Edwards, Kevin D Kreutter, David A Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L Wolin, Craig R Woods, Anne Fourie, Xiaohua Xue, Maxwell D Cummings: Secondary alcohol quinolinyl modulators of RORγt. Janssen Pharmaceutica, Yuriy P Stercho, December 29, 2015: US09221804 (12 worldwide citation)

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthri ...


2
Nalin Subasinghe, Ehab Khalil, Kristi A Leonard, Farah Ali, Heather Hufnagel, Jeremy M Travins, Shelley K Ballentine, Kenneth T Wilson, Maxwell D Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, Jonathan M Rudolph, Hui Huang: Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions. 3 Dimensional Pharmaceuticals, November 21, 2006: US07138530 (11 worldwide citation)

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmac ...


3
Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M Travins, Shelley K Ballentine, Kenneth T Wilson, Maxwell D Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M Jonathan Rudolph, Hui Huang: Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions. 3 Dimensional Pharmaceuticals, September 19, 2006: US07109354 (6 worldwide citation)

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceu ...


4
Tianbao Lu, Louis V Lafrance III, Daniel J Parks, Karen L Milkiewicz, Raul R Calvo, Maxwell D Cummings, Alexander J Kim, Bruce L Grasberger, Theodore E Carver Jr: Substituted 1,4-benzodiazepines and uses thereof. Laura Donnelly, June 27, 2006: US07067512 (3 worldwide citation)

The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently —C(O)—, —CH ...


5
Maxwell D Cummings, Robert Jr W Marquis, Ru Yu: Protease inhitors. Smithkline Beecham Co, zhao renlin zhang bengyuan, July 23, 2003: CN01808290 (2 worldwide citation)

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of at ...


6
Kristi A Leonard, Kent Barbay, James P Edwards, Kevin D Kreutter, David A Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L Wolin, Craig R Woods, Anne Fourie, Xiaohua Xue, Maxwell D Cummings, William Moore Jones, Steven Goldberg: Methylene linked quinolinyl modulators of RORγt. Yuriy P Stercho, March 15, 2016: US09284308 (1 worldwide citation)

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthri ...


7
Maxwell D Cummings, Robert W Marquis Jr, Daniel F Veber, Dennis S Yamashita: Protease inhibitors. SmithKline Beecham Corporation, Linda E Hall, Stephen A Venetianer, Charles M Kinzig, July 4, 2006: US07071184 (1 worldwide citation)

The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for ...


8

9
Kristi A Leonard, Kent Barbay, James P Edwards, Kevin D Kreutter, David A Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L Wolin, Craig R Woods, Maxwell D Cummings: Alkyl linked quinolinyl modulators of RORγt. Janssen Pharmaceutica, Yuriy P Stercho, May 24, 2016: US09346782

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthri ...


10
Kristi A Leonard, Kent Barbay, James P Edwards, Kevin D Kreutter, David A Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L Wolin, Craig R Woods, Xiaohua Xue, Maxwell D Cummings, Kelly McClure, Virginia Tanis: Quinolinyl modulators of RORγt. Janssen Pharmaceutica, Yuriy P Stercho, April 18, 2017: US09624225

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthri ...